Sign In
Buy ADC
$72.03
-0.650 (-0.89%)
At Close: Jun 03, 2026
Looking for Passive Income? These 3 High-Yield Dividend Stocks Cut You a Check Monthly.
06:30am, Saturday, 09'th Nov 2024
Dividend-paying stocks consistently outperform those that don't pay a dividend.
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why
01:14pm, Friday, 08'th Nov 2024
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here's Why
2 Overpriced REITs To Avoid And 1 Better Buy
08:15am, Thursday, 07'th Nov 2024
Not all REITs are worth buying. Some very popular REITs are today overpriced. I present two of them to avoid and one better alternative.
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
07:30am, Thursday, 07'th Nov 2024
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of
Rates Up, REITs Down! It's Opportunity Cost
07:00am, Thursday, 07'th Nov 2024
The recent 75 basis point rise in the 10-year treasury yield has led to a significant selloff in net lease REITs. Despite strong earnings, REITs like O and ADC have seen stock price declines due to in
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
09:47am, Tuesday, 05'th Nov 2024
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs
06:15pm, Monday, 04'th Nov 2024
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company de
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
04:05pm, Monday, 04'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format
ADC Therapeutics to Present at November Investor Conferences
07:15am, Monday, 04'th Nov 2024
LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced pa
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Friday, 01'st Nov 2024
LAUSANNE, Switzerland , Nov. 1, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
07:15am, Thursday, 31'st Oct 2024
LAUSANNE, Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
Agree Realty: A Strong Performance, But Preferreds Getting Less Attractive
11:36am, Wednesday, 30'th Oct 2024
Agree Realty's preferred dividends are extremely well-covered, requiring less than 2% of core FFO and AFFO, making them one of the safest in the REIT sector. The REIT's balance sheet is robust, with $
2 REITs To Avoid And 1 Strong Buy
08:25am, Tuesday, 29'th Oct 2024
Not all REITs are worth buying. This is a vast sector, and you need to be very selective. I highlight 2 REITs to sell and a better alternative.
Agree Realty: Quality Always Rises To The Top
06:56am, Tuesday, 29'th Oct 2024
Agree Realty remains a top-quality REIT with strong fundamentals, despite a less attractive yield compared to a year ago, offering solid long-term upside potential. The company has demonstrated robust
